Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): A population-based study, 1993–2007

Abstract

Chronic myelomonocytic leukemia is a very rare blood cancer observed mostly in the elderly. Here we report the incidence trends and survival of patients with chronic myelomonocytic leukemia over a 15-year period (1993-2007). Cases were provided by the population-based Girona Cancer Registry. The crude incidence rate was 0.72/100,000 inhabitants/year. No statistically significant increase in trends was detected over the 15 years. Median overall survival was 28 months although survival markedly decreased with advancing age. The 5-years observed and relative survival were 20% and 29%, respectively. This is the first population-based study that reports the incidence and survival of chronic myelomonocytic leukemia in Spain. Incidence and survival of chronic myelomonocytic leukemia in AbstractChronic myelomonocytic leukemia is a very rare blood cancer observed mostly in the elderly. Here we report the incidence trends and survival of patients with chronic myelomonocytic leukemia over a 15-year period (1993-2007). Cases were provided by the population-based Girona Cancer Registry. The crude incidence rate was 0.72/100,000 inhabitants/year. No statistically significant increase in trends was detected over the 15 years. Median overall survival was 28 months although survival markedly decreased with advancing age. The 5-years observed and relative survival were 20% and 29%, respectively. This is the first population-based study that reports the incidence and survival of chronic myelomonocytic leukemia in Spain.

Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population‐based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012

“…Our results show that RS was poor in all age groups and did not improve over the past two decades, which indicates the need to improve outcomes for CMML patients. The finding that survival is generally poor in CMML is congruent with other smaller series (Braun et al , ; Cheng et al , ; Osca‐Gelis et al , ; Visser et al , ; Ades et al , ); however, it has not been demonstrated before in a large population‐based study. Treatment options for CMML patients are limited and the vast majority are not eligible for curative treatment (i.e., allogeneic SCT) due to advanced age at diagnosis.…”

“…The diagnosis of CMML can be challenging as it primarily relies on morphological assessment of blood and bone marrow smears, along with cytogenetic evaluation, in patients with persistent monocytosis. Despite the wellknown diagnostic challenges in CMML, the overall ASR in our cohort is comparable with recent smaller studies from other Western countries (Osca-Gelis et al, 2012;Visser et al, 2012).…”

“…In this regard, population‐based studies can provide data complementary to findings from clinical trials by specifically addressing an unselected CMML population. So far, the few available population‐based studies in CMML have limitations, including small sample sizes, short study and follow‐up length, or registries that only partially cover the country (Osca‐Gelis et al , ; Visser et al , ).…”

The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands

“…Large nationwide population-based studies based on data from cancer registries and medical claims are currently lacking in CMML. The few available smaller studies had limitations such as a short study period or a cohort only partially covering the country [4,6,[22][23][24][25]. The overall ASR of CMML in the cohort of patients who underwent bone marrow examinations was half as low as the ASR in the NCR [20].…”

A case of mandibular osteomyelitis in a patient with chronic myelomonocytic leukaemia

“…The median age at diagnosis varies between 65 years and 75 years [1–4]. It has a 2:1 male predominance [5, 6].…”